{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-25-000045","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.998460+00:00","generated_at":"2026-05-17T19:08:27.125040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Travere Q2 2025: FILSPARI sales $71.9M (+165% YoY); net loss narrows to $12.8M","bullets":["U.S. FILSPARI net product sales $71.9M, up 165% YoY; 745 new patient start forms received in Q2.","Total revenue $114.4M including $17.5M milestone from CSL Vifor; net product sales total $94.8M.","Net loss $12.8M ($0.14/share) vs $70.4M loss ($0.91/share) in Q2 2024; non-GAAP net income $11.9M.","Cash $319.5M; sNDA for FSGS accepted with PDUFA Jan 13, 2026; IgAN REMS modification PDUFA Aug 28, 2025.","R&D expense $49.4M (-9% YoY); SG&A expense $76.2M (+18% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-25-000045","json":"https://secwatch.observer/filing/0001438533-25-000045.json","markdown":"https://secwatch.observer/filing/0001438533-25-000045.md","text":"https://secwatch.observer/filing/0001438533-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/0001438533-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/tvtx-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:08:27.125040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}